- Home
- ABTS vs APRE Comparison
ABTS vs APRE Comparison
Compare ABTS & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
BUY
Current Price
$2.78
N/A
Current Price
$0.89
Company Overview
Basic Information| Metric | ABTS | APRE |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 6.3M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ABTS | APRE |
|---|---|---|
| Price | $2.78 | $0.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | ★ 1.0M | 277.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $0.55 |
| 52 Week High | $10.86 | $2.76 |
Technical Indicators
Market Signals| Indicator | ABTS | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 43.52 | 62.05 |
| Support Level | $2.13 | $0.90 |
| Resistance Level | $4.98 | $1.02 |
| Average True Range (ATR) | 0.60 | 0.10 |
| MACD | 0.10 | 0.03 |
| Stochastic Oscillator | 22.57 | 97.95 |
Price Performance
Historical Comparison ABTS
APRE
About ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations. The group has its subsidiaries in USA, China, Canada and Hong Kong.
About APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.